Research & Development: Page 97
-
Technology's Impact on Business Processes
Phil Garland It is not enough to simply implement technology. Companies are going to have to change the way they do business. Bill Stevens Technology is an enabling component of the entire business. If the people within the business do not have the right information to act on a daily basis then a...
By Denise Myshko • Jan. 2, 2008 -
E-Media
Teranode Releases Life-Sciences R&D Platform, Pathway Analytics Solution Teranode Corp. has released Teranode Design Suite 2.5 (TDS 2.5), an enhanced, closed-loop R&D platform used to integrate modeling into existing informatics infrastructures. The platform improves research productivity...
By PharmaVoice Team • Jan. 2, 2008 -
Explore the Trendline➔
Stock via Getty ImagesTrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
PharmaOutlet
Contributed by Norman M. Goldfarb The Worst Informed Consent Ever: How Physicians Can Coerce and Unduly Influence Patients Informed consent requires that the potential subject be fully informed and capable of making a rational decision to participate in a clinical study. The attempt to incorporat...
By PharmaVoice Team • Jan. 2, 2008 -
Adelene Perkins -- People-Centric: Developing a Unified Vision
Early in her career, Adelene Perkins learned an important lesson about leadership: people work because they want to, not because they are told to. This truism has become a central plank of Ms. Perkins’ management style as she helps put together teams that will drive a company’s success. Central t...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaTrax
Biotech Drugs Will Be Hard Hit By Benefit Management Biologicals, which have received minimal pharmacoeconomic scrutiny from payers, increasingly will face the same strict value-based review and administration processes of pharmaceuticals, according to a 2005 study from The Bruckner Group Inc. (B...
By PharmaVoice Team • Jan. 2, 2008 -
Chief Risk Officers: Time for a Seat at The Table
VIEW on risk management Chief Risk Officers Time for a Seat at the Table In the wake of year one Sarbanes-Oxley compliance for U.S. public companies, there are greater challenges and increased expectations in addressing enterprise risk. Yet, compliance is not a matter of completing a one-year pro...
By PharmaVoice Team • Jan. 2, 2008 -
What's New
inChord Establishes The Navicor Group New agency to offer expertise in oncology and immunology. inChord Communications Inc. has launched The Navicor Group, a new advertising agency focused exclusively on companies marketing oncology and immunology products. “Today there are more cancer therapies ...
By PharmaVoice Team • Jan. 2, 2008 -
On the Calendar
On the Calendar April 17-19 Medical Manufacturing Summit The Homestead Resort, Hot Springs, Va. For more information, contact Caria Badenhorst, Marcus Evans, at 246-417-5321, e-mail [email protected], or visit medicalmanufacturingsummit.com. April 18-19 Neurodegeneration in Alzheimer’s, Pa...
By PharmaVoice Team • Jan. 2, 2008 -
Connecting the Dots
Ensuring trial-supply management is an integral part of overall clinical-trials management and manufacturing can bring efficiency to development and save companies time and money. Discussions about increasing efficiency and reducing time lines in clinical development often focus on patient and in...
By Denise Myshko • Jan. 2, 2008 -
Letter from the Editor
Building Consensus Dendrite hosted its Second Annual Pharmaceutical Sales and Marketing Leadership Conference in New York last October. One of the many highlights of the event was the keynote address given by President George H.W. Bush to more than 400 attendees, including heads of some of the wo...
By Taren Grom • Jan. 2, 2008 -
Table of Contents
on the cover Sea change: Turning the tide — the product life-cycle management wave Life-science executives are turning to product life-cycle management earlier in development to maximize product value and combat the impact of the dying blockbuster model. 12 FEATURES Connecting the dots Ensuring t...
By PharmaVoice Team • Jan. 2, 2008 -
Cover
THE FORUM FOR THE INDUSTRY EXECUTIVE February 2005 www.pharmavoice.com INTEGRATING OPERATIONS Product Life-Cycle Management SEARCHING FOR ANSWERS with Peter Milner SUPPLY-CHAIN Management Download PDF
By PharmaVoice Team • Jan. 2, 2008 -
Letter from the Editor
The Paper Chase The paperless clinical trial has yet to come to fruition. According to a recent Forrester Research survey of 400 CRAs and CRCs, 97% of current data-capture practices are still done via paper, 50% are through remote data entry, 35% are through scanning/fax, 25% are Web-enabled, 22%...
By Taren Grom • Jan. 2, 2008 -
Table of Contents
November 2003 Contents 8 Keith Howells says the use of wireless devices at the point of care will increase. 32 For Jed Beitler, CRM — not DTC — is better suited for patient compliance. 44 Dr. Sidney Pestka is leading an interferon revolution. On the Cover The continuing evolution of EDC Electroni...
By PharmaVoice Team • Jan. 2, 2008 -
Cover
November 2003 The Forum for the Industry Executive Electronic Data Capture Coming of Age Pushing Science Forward with Sidney Pestka DTC’s Role in Improving Compliance Download PDF
By PharmaVoice Team • Jan. 2, 2008 -
What's on Your Mind -- Opinions
What’s on your mind opinions Preferred-provider status Increasingly, companies that provide services to the life-sciences industry are required to be on a preferred provider list. In the November issue of PharmaVOICE, we asked are innovative/new ideas being overlooked in some cases because a serv...
By PharmaVoice Team • Jan. 2, 2008 -
Table of Contents
December 2003 Contents 8 Cyndi Verst-Brasch says Phase IV trials have to withstand regulatory vigor. 20 Pharma is becoming more involved in choosing investigator sites, says Mark Eisenach. 32 For Dr. John Patton, the life sciences are awe inspiring. on the cover The value of Phase IV Postmarketin...
By PharmaVoice Team • Jan. 2, 2008 -
The Art of Site Selection
By Denise Myshko The Art of Site Selection For pharmaceutical sponsors and their CRO partners, selecting the right investigator site is a linchpin to trial success. Quality sites have to have a well-trained staff, a patient-recruitment plan, experience in meeting or beating enrollment targets, lo...
By Denise Myshko • Jan. 2, 2008 -
Letter from the Editor
letter from the editor Phase IV studies can help differentiate a product from its competitors, medically support marketing objectives and messages, develop and enhance relationships with clinical investigators and key opinion leaders, increase physician exposure to a new drug, answer scientific q...
By Taren Grom • Jan. 2, 2008 -
Cover
December 2003 The forum for the industry executive PHASE IV TRIALS Balancing marketing and science adventuring forth with John Patton Marketing to nps and pas Download PDF
By PharmaVoice Team • Jan. 2, 2008 -
PharmaTrax
Sales, marketing, And R&D Trends affecting the healthcare industry Profitable Biotech Companies Predicted to double in Next Few Years Therapeutic proteins and therapeutic antibodies collectively comprise almost 75% of biotech drugs currently on the market. Protein drugs also represent one of ...
By PharmaVoice Team • Jan. 2, 2008 -
E-Media
New electronic and web-based applications, sites, and technologies Solutions From PHT Provide Clinical Trial Savings and Flexibility Two recently launched offerings from PHT Corp., LogPad Phone and the Technology Transfer Program, aim to make the electronic capture of clinical-trial information e...
By PharmaVoice Team • Jan. 2, 2008 -
E-Media
E-Media New electronic and web-based applications, sites, and technologies Health Research International Launches Online Survey Capability Health Research International has launched its real-time, online survey capability. The online format complements the companyís existing survey expertise, enc...
By PharmaVoice Team • Jan. 2, 2008 -
Pharmacogenomics: The Next Step Forward
Pharmacogenomics The Next Step Forward The first NDA based on pharmacogenomic data may still be a long time coming, but in anticipation of such filings, the FDA has issued a draft guidance that encourages companies to conduct pharmacogenomic tests during the drug-development process. Pharmacogeno...
By Denise Myshko • Jan. 2, 2008 -
What's New
What’s new New healthcare-related products, services, and companies The HBA – A National Brand The Healthcare Businesswomenís Association has undergone a reorganization and created a new Northeast Corridor Metro Chapter to better serve its members. The Healthcare Businesswomen’s Association (HBA)...
By PharmaVoice Team • Jan. 2, 2008